TWST
Twist Bioscience·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TWST
Twist Bioscience Corporation
A US provider of synthetic biology solutions, including DNA synthesis and gene editing tools
Biological Technology
02/04/2013
10/31/2018
NASDAQ Stock Exchange
979
09-30
Common stock
681 Gateway Blvd, South San Francisco, CA 94080
--
Twist Bioscience Corporation was incorporated in Delaware on February 4, 2013. The company is committed to serving customers who are making the world a better place. In the fields of health care, food/agriculture, industrial chemicals, academic research and data storage, customers are using their synthetic DNA tools to develop ways to improve lives and improve the sustainability of the planet. They developed a disruptive DNA synthesis platform to industrialize biological engineering to provide DNA for a wide range of uses and markets. They combined silicon-based DNA writing technology with proprietary software, scalable business infrastructure and e-commerce platform to create an integrated technology platform.
Earnings Call
Company Financials
EPS
TWST has released its 2025 Q4 earnings. EPS was reported at -0.45, versus the expected -0.5, beating expectations. The chart below visualizes how TWST has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TWST has released its 2025 Q4 earnings report, with revenue of 99.01M, reflecting a YoY change of 16.88%, and net profit of -27.14M, showing a YoY change of 21.69%. The Sankey diagram below clearly presents TWST's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available


